SUPPLEMENTAL MATERIAL. Role of Titin Missense Variants in Dilated Cardiomyopathy

Similar documents
Focusing on results not data comprehensive data analysis for targeted next generation sequencing

Disease gene identification with exome sequencing

BRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls?

Next Generation Sequencing. mapping mutations in congenital heart disease

Genotypes of patients with factor VII deficiency

Breast cancer and the role of low penetrance alleles: a focus on ATM gene

Genetic Mutations Cause Many Birth Defects:

Next Generation Mendelian Genetics by Exome Sequencing. Jay Shendure, MD, PhD Dept. of Genome Sciences University of Washington

Big Data for Population Health

Names for MNS Blood Group Alleles

Leading Genomics. Diagnostic. Discove. Collab. harma. Shanghai Cambridge, MA Reykjavik

Delivering the power of the world s most successful genomics platform

Targeted Cancer Gene Analysis For Research Use Only - Not Intended for Clinical Use

Outcome Data, Links to Electronic Medical Records. Dan Roden Vanderbilt University

All in a highly interactive, easy to use Windows environment.

Milk protein genetic variation in Butana cattle

DNA Sequencing and Personalised Medicine

Genetic Long QT Syndrome GENETIC TESTING FOR LONG QT SYNDROME HS-148. Policy Number: HS-148. Original Effective Date: 1/21/2010

White paper Evaluation of BRAF (V600E) Mutation by Immunohistochemical Staining with anti-braf V600E (VE1) Antibody: A Comparison with Sanger

Introduction to genetic testing and pharmacogenomics

Current Motif Discovery Tools and their Limitations

On-line supplement to manuscript Galaxy for collaborative analysis of ENCODE data: Making large-scale analyses biologist-friendly

SMRT Analysis v2.2.0 Overview. 1. SMRT Analysis v SMRT Analysis v2.2.0 Overview. Notes:

Tools for human molecular diagnosis. Joris Vermeesch

Genomes and SNPs in Malaria and Sickle Cell Anemia

Curriculum Vitaè. Office of Registrar 414 East Clark Street Vermillion, South Dakota 57069

OpenMedicine Foundation (OMF)

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE

NOVEL FOXC2 MISSENSE MUTATION IDENTIFIED IN PATIENT WITH LYMPHEDEMA-DISTICHIASIS SYNDROME AND REVIEW

Genetic diagnostics the gateway to personalized medicine

European Educational Programme in Epidemiology

Introduction to NGS data analysis

Genetic testing for Gilbert s syndrome: how useful is it in determining the cause of jaundice?

Resumen Curricular de los Profesores. Jesse Boehm

1. Oblast rozvoj spolků a SU UK 1.1. Zvyšování kvalifikace Školení Zapojení do projektů Poradenství 1.2. Financování

Hypertrophic cardiomyopathy (HCM) is the most

The NF1-gene a hotspot for de novo Alu- and L1-insertion?

Final Project Report

USE OF BUSINESS PROCESS MANAGEMENT TECHNOLOGY AND LEAN TO IMPROVE CARE

8 9 +

These case studies were developed by NHGRI and DO NOT REPRESENT official guidance for FDA regulations. IDE risk determinations will always depend on

Exercises for the UCSC Genome Browser Introduction

The Future of the Electronic Health Record. Gerry Higgins, Ph.D., Johns Hopkins

Targeted. sequencing solutions. Accurate, scalable, fast TARGETED


SeqArray: an R/Bioconductor Package for Big Data Management of Genome-Wide Sequence Variants

Becker Muscular Dystrophy

ADO - Omics Data Analysis

Text file One header line meta information lines One line : variant/position

User guide for referring samples to the IBGRL Molecular Diagnostics Laboratory

NIH/NIGMS Trainee Forum: Computational Biology and Medical Informatics at Georgia Tech

University of Southern California ivip Guest/Affiliate System

SEQUENCING INITIATIVE SUOMI (SISU) SYMPOSIUM SPEAKERS August 26, 2014

Preparing for the Collection and Use of External Family History and Genetic Test Result Data

How To Identify Ankylosing Spondylitis In Chinese People

Intro to Bioinformatics

THE UNIVERSITY OF MANCHESTER Unit Specification

NEXT GENERATION SEQUENCING

SNPbrowser Software v3.5

Database schema documentation for SNPdbe

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

Biological Sciences Initiative. Human Genome

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System

1 Mutation and Genetic Change

Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy

Meeting Requirements for Pharmacy School Admission. Deb Cieplak UAA Pre-Pharmacy Adviser October 18, 2011

WORKING GROUP ON BIOCHEMICAL AND MOLECULAR TECHNIQUES AND DNA-PROFILING IN PARTICULAR. Eighth Session Tsukuba, Japan, September 3 to 5, 2003

The Case of Baby Joe by Kristen L.W. Walton Page 1

Sanger Sequencing and Quality Assurance. Zbigniew Rudzki Department of Pathology University of Melbourne

Bioinformatics Resources at a Glance

Indication criteria for disease: Tuberous sclerosis (TSC) [TSC1, TSC2]

Clinical and research data integration: the i2b2 FSM experience


Index. Registry Report

SeqHBase: a big data toolset for family-based sequencing data analysis

Europass Curriculum Vitae

SeqArray: an R/Bioconductor Package for Big Data Management of Genome-Wide Sequencing Variants

Ph.D. in Bioinformatics and Computational Biology Degree Requirements

The Galaxy workflow. George Magklaras PhD RHCE

Prevention Status Report 2013

Information leaflet. Centrum voor Medische Genetica. Version 1/ Design by Ben Caljon, UZ Brussel. Universitair Ziekenhuis Brussel

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

The 100,000 genomes project

Roberto Ciccone, Orsetta Zuffardi Università di Pavia

Genetics of Rheumatoid Arthritis Markey Lecture Series

Data Analysis for Ion Torrent Sequencing

DNA Sequence Alignment Analysis

Links to ProgressiveAgent.com available for use on agent Web sites

Towards a Big Data Taxonomy. Bill Mandrick, PhD Data Tactics Version 26_August_2013

Exome sequencing e targeted sequencing in diagnostica e ricerca applicata: pro e contro

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

How To Find Rare Variants In The Human Genome

Funding Opportunities Starter Grants

Innovation Platform: Sudden Cardiac Death

Genetic Testing for CHEK2 Mutations for Breast Cancer

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

The Search for Anticoagulant Resistance in Rats in New Zealand

Transcription:

SUPPLEMENTAL MATERIAL Role of Titin Missense Variants in Dilated Cardiomyopathy Running title: Begay et al. TTN missense variants in DCM Rene L. Begay, BS 1, Sharon Graw, PhD 1, Gianfranco Sinagra, MD 2, Marco Merlo, MD 2, Dobromir Slavov, PhD 1, Katherine Gowan 3, Kenneth L. Jones, PhD 3, Giulia Barbati, PhD 2, Anita Spezzacatene, MD 2, Francesca Brun, MD 2, Andrea Di Lenarda, MD 2, John E. Smith, PhD 4, Henk L. Granzier, PhD 4, Luisa Mestroni, MD 1, Matthew Taylor, MD, PhD 1, on behalf of the Familial Cardiomyopathy Registry 1 University of Colorado Denver CU-Cardiovascular Institute, Aurora, CO; 2 Cardiovascular Department Ospedali Riuniti and Cardiovascular Center, ASS1-Trieste and University of Trieste, Trieste, Italy; 3 Department of Biochemistry and Molecular Genetics, University of Colorado, Aurora, AZ; 4 Molecular Cardiovascular Research Program, University of Arizona, Tucson, AZ Correspondence: Matthew Taylor, MD, PhD, Division of Cardiology, University of Colorado Health Sciences Center, 12700 East 19th Ave, F442, Room 8022, Aurora, CO 80045. E-mail matthew.taylor@ucdenver.edu 1

Supplemental Figure Figure S1. Venn Diagram of SIFT/PolyPhen2/GERP Relationships SIFT 63 2 PolyPhen2 0 151 111 4 GERP 4 Unmet all 3 criteria 13 Figure S1. Displayed are GERP, PolyPhen2 prediction, and SIFT scores for all 348 TTN missense variants. This figure shows the distribution of the variants that met all cutoff criteria, none, or met only two or one of the three bioinformatic filtering criteria. 2

Supplemental Tables Table S1. Sequential Bioinformatic Filter Criteria of TTN Variants. Variant Filter Inclusion Criteria 1) Total sequence data of 147 families (non-synonymous, synonymous, intronic, frameshift, exonic, and intergenic) 2) Non-synonymous variants only - Excluded 13 families harboring truncation mutations* Number of Variants 814 348 3) Variants with SIFT score = 0 327 4) PolyPhen2 HVAR possibly damaging and damaging predictions 170 5) Number of Mutations 2 124 6) Exclude, if present in 1000 Genome database 83 7) Exclude if allele frequency 0.04% in Exome Sequencing Project (n=5,400 subjects) 65 8) GERP RS score 4.2 44 * Previously reported by Herman, et al. 1 3

Table S2. Bioinformatic Data for the 44 severe TTN Rare Variants. ID Mutation Polyphen2 Prediction RS Number GERP+RS ESP5400 AA; EA Frequency TTN-238839 Pro23170Arg P;P;P;P 72646900 4.39 0; 0 TTN-088762 Ser7409Pro P 17452588 4.71 0; 0 TTN-178217 Arg12999Cys D;D;D;D 72650088 4.87 0; 0 TTN-245906 Arg25922Cys P;P;P;P 72648214 4.95 0; 0 TTN-245973 Ser25944Tyr P;P;P;P 72648215 4.96 0; 0 TTN-095345 Gly8569Arg P 72648991 4.98 0; 0 TTN-236246 Ala22702Thr P;P;P;B 72646895 5.21 0.000316; 0 TTN-172724 Ser12061Pro D;D;D;D 72650078 5.38 0; 0 TTN-275613 Lys32652Glu P;P;P;P 72629783 5.41 0; 0.0003 TTN-259628 Trp24693Arg D;D;D;D 72648246 5.48 0; 0 TTN-189481 Arg13843Met D;D;D;D 72677229 5.49 0; 0 TTN-026760 Glu1039Gly B;B;B;B;P 72647868 5.54 0; 0 TTN-233699 Tyr21853His P;P;P;P 72646888 5.6 0; 0 TTN-034409 Ala2258Val D;D;D;D;D 72647881 5.62 0; 0 TTN-199079 Arg30897His D;D;D;D 72632860 5.63 0.000319; 0.00015 TTN-272197 Gly31678Arg D;D;D;D 72648279 5.65 0; 0 TTN-254388 Leu27858Arg P;P;P;P 72648234 5.66 0; 0.000301 TTN-254689 Gly27921Asp D;D;D;D 72648235 5.66 0; 0.000296 4

TTN-230280 Phe21012Leu D;D;D;D 72646877 5.68 0; 0 TTN-232757 Glu21576Gly D;D;D;D 72646884 5.72 0; 0 TTN-254772 Glu27949Gln P;P;P;P 72648236 5.76 0; 0 TTN-257524 Gly28717Glu D;D;D;D 72648243 5.76 0; 0 TTN-251996 Ser27662Gly B;P;P;P 72648231 5.77 0; 0 TTN-263807 Arg30215Gly D;D;D;D 72648261 5.81 0; 0 TTN-263385 Ile30116Thr D;D;D;D 72648259 5.82 0; 0.000295 TTN-188497 Ile13613Phe P;P;P;P 72677226 5.83 0; 0 TTN-275968 Ile32770Asn D;D;D;D 72629784 5.83 0; 0 TTN-226981 Arg20388His D;D;D;D 72646868 5.86 0; 0.000151 TTN-270677 Arg31411His D;D;D;D 72648276 5.87 0.000313; 0 TTN-244241 Tyr30201Asp D;D;D;D 72648211 5.88 0; 0 TTN-009517 Glu222Lys P;P;P;P;P 72647844 5.92 0; 0 TTN-197931 Glu15297Gln P;P;P;P 72677250 5.95 0; 0 TTN-274444 Arg32262Leu D;D;D;D 72629782 5.95 0; 0 TTN-276694 Arg33012Leu P;P;P;P 72629786 5.95 0; 0 TTN-221566 Leu19535Ser D;D;D;D 72646854 6.01 0; 0 TTN-175395 Thr12542Ala P;P;P;P 72650081 6.06 0; 0 TTN-195470 Leu21219His D;D;D;D 72677245 6.07 0; 0 TTN-236765 Val22875Ile D;D;D;D 72646897 6.07 0; 0 5

TTN-247572 Arg26477His D;D;D;D 72648220 6.1 0; 0 TTN-218441 Ser18632Tyr D;D;D;D 72646844 6.11 0; 0 TTN-216342 Arg18064Cys D;D;D;D 72646839 6.16 0.00032; 0 TTN-224394 Pro19922Ala D;D;D;D 72646860 6.17 0; 0.000152 Table S2. Displayed are Polyphen2 HDVAR predictions as described, 3,4 and the multiple predictions in PolyPhen2 refer to their multiple isoforms. D: Damaging by Polyphen2, P: probably damaging by Polyphen2 criteria. The variants listed are from families with 2 mutations predicted, per our bioinformatic filtering strategy. The table also includes GERP scores for severe TTN missense variants that had SIFT scores of zero and were absent in the 1,000 Genomes dataset. The data show ESP scores below the cutoff of 0.04%. 2 6

Table S3. Primer Sequences and PCR Conditions. Mutation Primer Name (RS number) Primer Sequence Ser>Gly rs72648231 F TCGAGAAAGCATCACTGTGG R GCCAAGACTGGTTCAGAAGG Arg>His rs72648220 F ATATGATGGTGGCTGCCAAA R GGATACTCTGCAACAACAGCT Arg>Cys rs72650088 F R TTAGCAAAGCAGATGCACCA GCACAAATAACCCCAATGCT Glu>Gln rs72648236 F GGCCTCCAGCTGATGATG R CAAATGCGTTCTTGGCTACA 7

References 1. Herman DS, Lam L, Taylor, MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, Teodorescu DL, Cirino AL, Banner NR, Pennell DJ, Graw S, Merlo M, Di Lenarda A, Sinagra G, Bos JM, Ackerman MJ, Mitchell RN, Murry CE, Lakdawala NK, Ho CY, Barton PJ, Cook SA, Mestroni L, Seidman JG, Seidman CE. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-628. 2. Norton N, Robertson PD, Rieder MJ, Zuchner S, Rampersaud E, Martin E, Li D, Nickerson DA, Hershberger RE, National Heart, Lung and Blood Institute GO Exome Sequencing Project. Evaluating pathogenicity of rare variants from dilated cardiomyopathy in the exome era. Circ Cardiovasc Genet 2012;5:167-174. 3. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248-9. 4. Maathuis MH, Colombo D, Kalisch M, Bühlmann P. Predicting causal effects in large-scale systems from observational data. Nat Methods 2010;7:247-8. 8